HIV-Associated Neurocognitive Disorder When Antiretroviral Therapy Has Not Achieved Sustained Viral Suppression

HIV-associated neurocognitive disorder (HAND) requires escalation when initial antiretroviral therapy — including CNS-penetrating agents — has not achieved the viral suppression needed to halt neurological damage, leaving residual cognitive symptoms unresolved.

Previous Treatment & Why This Protocol Is Needed

Prior therapy: Antiretroviral therapy (ART), including CNS-penetrating agents such as efavirenz or raltegravir, initiated as early as possible after HIV diagnosis.

Unmet goal triggering escalation: Failure to achieve and maintain HIV viral suppression in the systemic and CNS compartments — the primary condition required before residual cognitive burden can be adequately addressed.

Next-Step Approach

Partial overview — complete regimen available in the full protocol

The next management step involves adjunctive therapies layered onto ART to address residual cognitive symptoms. These span agents with neuroprotective properties, medications targeting attention and concentration deficits, and structured rehabilitative interventions. Specific agents, selection criteria, rehabilitative components, and supportive care detail are set out in the full structured protocol below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1097/MD.0000000000035652

Antioxidants have gained attention as potential adjunctive therapies for HAND due to their neuroprotective properties.
N-acetylcysteine is a promising antioxidant that may help reduce oxidative stress and inflammation in the brain.
Coenzyme Q10 is another antioxidant that has been explored for its neuroprotective effects.
Omega-3 fatty acids, found in fish oil, have anti-inflammatory properties and may offer some cognitive benefits.
Psychostimulants are medications that may be considered in managing HAND, primarily to address cognitive deficits, including problems with attention and concentration.
Methylphenidate, commonly used to treat attention deficit hyperactivity disorder (ADHD), has been studied in individuals with HAND. It may improve attention and cognitive function.
Modafinil is another psychostimulant investigated for its potential to enhance alertness and cognitive performance in individuals with HAND.
Cognitive rehabilitation programs are essential components of HAND management. These programs involve cognitive training and strategies to help individuals with HAND improve their daily functioning, memory, and problem-solving skills.
Supportive care measures, including mental health counseling, occupational therapy, and social support, are integral in addressing the mental health implications of HAND and enhancing the quality of life for affected individuals.

View source ↗